Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166707 | 0.77 | KMT2A (0.63) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL13915687 | 0.77 | KMT2A (0.63) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3590498 | 0.74 | USP2 (0.65) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6859536 | 0.74 | CCR5 (0.48) | — | |
| SCHEMBL3595934 | 0.73 | KMT2A (0.78) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL16250460 | 0.73 | KMT2A (0.78) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3595931 | 0.73 | KMT2A (0.78) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL15249477 | 0.73 | KMT2A (0.78) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1886766 | 0.73 | KMT2A (0.78) | USP2L3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4274767 | 0.73 | L3MBTL1 (0.68) | USP2L3MBTL1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171353-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5) | CCR5, CXCR1, CCR7 | USP2 4480/4885L3MBTL1 3613/4885KMT2A 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.